Monoclate P (Antihemophilic factor [human] factor VIII) for Hemophilia | MyHemophiliaTeam

Connect with others who understand.

sign up Log in
About MyHemophiliaTeam
Powered By

Monoclate P is approved by the Food and Drug Administration (FDA) to control bleeding episodes and for perioperative (before, during, and after surgery) care in adults and children with factor VIII deficiency due to hemophilia A. The technical name of Monoclate P is Antihemophilic factor [human] factor VIII:C pasteurized monoclonal antibody purified.

Monoclate P is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Monoclate P is given as an intravenous injection.

Monoclate P comes in single-use vials and must be reconstituted before injection.

Side effects
The FDA-approved label for Monoclate P lists common side effects including mild chills, nausea, allergic reactions, and stinging at the injection site.

Serious side effects listed for Monoclate P include hypersensitivity reactions and the development of inhibitors.

For more details about this treatment, visit:

Monoclate P - CSL Behring

Treatment of Hemophilia - Hemophilia Federation of America

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in